Seattle Genetics pulls out of $2 billion bid for cancer drug

BOTHELL —Seattle Genetics, the region’s biggest biotech firm, spiked a $2 billion deal to manfuacture and distribute an experimental tumor fighting drug.

The company announced in February that it had reached a deal with New Jersey-based Immunomedics for exclusive worldwide rights to develop IMMU-132, which could fight tumors in breast, lung and bladder cancers. Seattle Genetics agreed to pay $250 million upfront, with licensing payments potentially reaching as much as $2 billion.

A large shareholder in Immunomedics, venBio Select Advisor thought the deal undervalued the anti-cancer drug. In March, it filed a lawsuit to block the agreement.

On Wednesday, shareholders led by venBio ousted the husband-and-wife team leading Immunomedics and approved a plan for the company to make and distribute IMMU-132.

The deal would be “nice to have,” but is “not a must have,” Seattle Genetics’ chief operating officer Eric Dobmeier said, according to Seeking Alpha, an investment news website.

Seattle Genetics has grown substantially in recent years, and expects to grow further in the next few years.

The company will focus its “full attention and resources to our promising pipeline and the substantial opportunities in front of us,” chief executive officer Clay Siegall said.

Its current product, Adcetris, could soon become a go-to drug for treating one of the main types of lymphoma. Seattle Genetics expects to bring several drugs to market in the next few years. The company plans to add 200 employees this year, raising its workforce to more than 1,100.

Dan Catchpole: 425-339-3454; dcatchpole@heraldnet.com; Twitter: @dcatchpole.

Talk to us

More in Herald Business Journal

Contractor getting $5M bonus for Hanford vitrification plant

The project will turn radioactive waste into a stable glass form for disposal.

SpaceX captures the flag, beating Boeing in cosmic contest

Elon Musk’s company is the first private firm to launch a crew to the International Space Station.

County staff urges ‘no’ on Point Wells development proposal

County Hearing Examiner Peter Camp could decide the fate of the high-rise project this summer.

Alderwood mall is ready for the governor’s green light

The Lynnwood shopping center, closed since March 24, could reopen in June. But expect changes.

Snohomish County seeks to enter second phase of reopening

The variance request will go to the state if approved by the Board of Health and the County Council.

Firm accused of violating eviction ban agrees to restitution

About 1,450 tenants, including some in Marysville, will receive rent refunds or direct payments.

Texan comes to defend Snohomish outlaw barber cutting hair

Bob Martin is defying orders to close. The man he calls his attorney didn’t go to law school.

Hundreds of masked guests line up as Tulalip casinos reopen

Tulalip Resort Casino and Quil Ceda Creek opened the doors on Tuesday after a two-month closure.

Boeing workers cope with the virus threat as layoffs loom

Five weeks after they returned to work, Boeing workers say measures inside the plants are mostly working.

Boeing cutting more than 12,000 jobs with layoffs, buyouts

The company said it will lay off 6,770 workers this week, and another 5,520 are taking buyouts.

Worst jobless rate in the state: Snohomish County at 20.2%

In April, 91,383 were unemployed in the county. The aerospace sector was hit especially hard.

Small business relief effort inundated with 850 applications

The economy in and around Everett has struggled amid fallen revenues and uncertainty about the future.